InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences, the leader in glycoproteomics, today announced the accomplishment of multiple milestones in advancing the world’s first glycoproteomics-based LDT(Lab-Developed Test). The company’s first diagnostic product, a noninvasive liquid biopsy test for ovarian cancer, will have final data from its initial clinical trial, V.O.C.A.L.™, in the first half of 2021; and […]